Press Releases

Year

June 7, 2021

Centessa Pharmaceuticals to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

CAMBRIDGE, Mass. and LONDON, June 07, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, M.D., Ph.D., Chief Executive Officer, will participate in an analyst-led fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on

June 4, 2021

Centessa Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs

CAMBRIDGE, Mass. and LONDON, June 04, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Centessa”), a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, announced today that, in connection

May 27, 2021

Centessa Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass. & LONDON --(BUSINESS WIRE)--May 27, 2021-- Centessa Pharmaceuticals plc (“Centessa”), a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, announced today the pricing of its

May 17, 2021

Centessa Pharmaceuticals Announces Expansion of Management Team and Board of Directors

New Appointments Bring Expertise and Proven Leadership to Support Asset‐Centric R&D Model and Portfolio Advancement CAMBRIDGE, Mass. & LONDON, May 17, 2021 – Centessa Pharmaceuticals (“Centessa”) today announced key additions to its leadership team and Board of Directors.

May 11, 2021

Centessa Pharmaceuticals Appoints Gregory Weinhoff, M.D., M.B.A., as Chief Financial Officer and Expands Board of Directors

CAMBRIDGE, Mass. & LONDON--( BUSINESS WIRE )--Centessa Pharmaceuticals (“Centessa”), a pharmaceutical company consisting of 10 subsidiary companies advancing a portfolio of high conviction programs with strong biological validation, today announced key additions to its leadership team.

May 10, 2021

Centessa Pharmaceuticals Appoints One of the World’s Leading Drug Developers, Antoine Yver, M.D., M.Sc., as Chief Medical Officer

CAMBRIDGE, Mass. & LONDON, May 10, 2021 – Centessa Pharmaceuticals (“Centessa”) today announced that Antoine Yver, M.D., M.Sc., has been appointed as Chief Medical Officer. Dr. Yver is one of the world’s leading drug developers with more than 30 years of global experience in the pharmaceutical

February 16, 2021

Centessa Pharmaceuticals Launches with $250 Million Series A Financing and Unveils a New Kind of Pharmaceutical R&D Model

Merger of 10 Privately Held Biotech Companies with Highly Validated Programs Led by Industry Leading Teams to Operate Under Centessa Umbrella Company Founded by Medicxi with Financing Led by General Atlantic, and Co-led by Vida Ventures and Janus Henderson Investors Saurabh Saha, M.D., Ph.D.,

Investors & Media